Will new COVID-19 treatments be as elusive for poor countries as vaccines?
Unlike vaccine manufacturers Pfizer and Moderna, which have resisted calls for license agreements to let overseas manufacturers make their shots, Merck will allow generic manufacturers in India to sell the pills at a far lower price in more than 100 poorer countries.
FDA likely to rule on virus pill in December
The panelists are likely to vote on whether Merck's drug should be approved, although the FDA is not required to follow their advice Procter & Gamble Health Ltd - 500126 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Zeal ShahDesignation :- Company Secretary and Compliance Officer
COVID-19: Everest Organics starts making ingredient for Merck's molnupiravir drug
Merck has separately entered into voluntary licensing agreements with at least eight Indian generic drugmakers for molnupiravir, to turn the country into a manufacturing hub for the drug.
A step from Covid-19 pills as Merck & Co seeks FDA approval
An application was submitted with the Food and Drug Administration for molnupiravir to treat mild-to-moderate Covid-19 in adults at risk of developing a severe illness that may require hospitalization Merck, Ridgeback approach FDA for EUA
Submission based on positive' interim findings of Phase III trials
Aurobindo Pharma to stop molnupiravir trial in moderate COVID-19 patients
Merck earlier this year suspended its own development of molnupiravir as a treatment for hospitalized COVID-19 patients since many of them have reached a phase of the disease that is too late for an antiviral drug to provide much help. Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Intimation Of The Board Meeting Scheduled To Be Held On November 9, 2021
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 9, 2021, inter alia, to consider and approve the unaudited financial results for the quarter ended September 30, 2021. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to regulation 39(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015,we hereby inform you regarding issue of duplicate share certificate(s) to the shareholder(s) of the Company, on October 6,2021. We request you to take the same on record and acknowledge the receipt. Deal signed with Singapore on Covid antiviral pill: Merck
Molnupiravir would be the first oral antiviral medication for Covid-19